JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wurtman, R. J.
Right arrow Articles by Rose, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wurtman, R. J.
Right arrow Articles by Rose, C.
Journal of Pharmacology And Experimental Therapeutics, Vol. 174, Issue 3, 351-356, 1970
Copyright © 1970 by American Society for Pharmacology and Experimental Therapeutics

THE FATE OF C14-DIHYDROXYPHENYLALANINE (C14-DOPA) IN THE WHOLE MOUSE

R. J. Wurtman 1, C. Chou 1, and C. Rose 1

1 Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts

The metabolic fate of i.p. administered C14-DL-dopa was examined in the whole mouse. The amino acid was rapidly destroyed at an initial rate (7.3% of injected dose per min) that was maintained for almost 10 minutes. The level of C14-catecholamine in the whole carcass reached a peak 20 minutes after injection; almost all of this material was C14-dopamine. Less than 0.1% of the C14-catechols present in the body 20 or 60 minutes after C14-DL-dopa administration was found in the brain. At all doses studied (0.5-150 mg/kg), more than half of the Cl4-dopa was metabolized during the first 20 minutes after its administration to C14-methoxydopa and Cl4-homovanillic acid. If the metabolism of the circulating amino acid in humans is similar to that of mice, it can be calculated that the amount of methionine needed to O-methylate the doses of L-dopa commonly used in parkinsonian patients may be greater than the average daily methionine intake.

Submitted on March 19, 1970
Accepted on June 2, 1970




This article has been cited by other articles:


Home page
 Physiol. Rev.Home page
E. E. Muller, V. Locatelli, and D. Cocchi
Neuroendocrine Control of Growth Hormone Secretion
Physiol Rev, April 1, 1999; 79(2): 511 - 607.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
B. F. Weiss, H. N. Munro, L. A. Ordonez, and R. J. Wurtman
Dopamine: Mediator of Brain Polysome Disaggregation after L-Dopa
Science, August 18, 1972; 177(4049): 613 - 616.
[Abstract] [PDF]

Home page
 ScienceHome page
R. Hoeldtke, B. S. Baliga, P. Issenberg, and R. J. Wurtman
Dihydroxyphenylalanine in Rat Food Containing Wheat and Oats
Science, February 18, 1972; 175(4023): 761 - 762.
[Abstract] [PDF]

Home page
 ScienceHome page
B. F. Weiss, H. N. Munro, and R. J. Wurtman
L-Dopa: Disaggregation of Brain Polysomes and Elevation of Brain Tryptophan
Science, August 27, 1971; 173(3999): 833 - 835.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1970 by the American Society for Pharmacology and Experimental Therapeutics.